Antituberculosis treatment-induced hepatotoxicity: role of predictive factors
Open Access
- 1 June 1995
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Postgraduate Medical Journal
- Vol. 71 (836) , 359-362
- https://doi.org/10.1136/pgmj.71.836.359
Abstract
Antituberculosis drug-induced hepatotoxicity is quite common. However, factors predicting its development are still controversial. The objective of the present study was to evaluate the role of certain factors (age and sex of the patient, alcoholism, chronic liver disease, hepatitis B virus carrier status, acetylator status, nutritional status and antituberculosis treatment (ATT) regimen) in predicting the development of ATT-induced hepatitis. In a case-control study, 60 consecutive patients with evidence of ATT-induced hepatitis were studied to assess the possible association of the above-mentioned factors with ATT-induced hepatitis. Body mass index was found to be significantly lower in ATT-induced hepatitis patients (17.2 +/- 2.7) than in controls (19.5 +/- 3.3) (p < 0.05). Pyrazinamide was used in addition to isoniazid and rifampicin in a significantly higher percentage of patients in the ATT-induced hepatitis group (70%) as compared with those in the control group (42%). No significant differences were observed between the two groups with regard to the rest of the parameters.Keywords
This publication has 27 references indexed in Scilit:
- Drug Treatment of Tuberculosis - 1992Drugs, 1992
- Hepatotoxicity of Rifampin and Isoniazid: Is It All Drug-induced Hepatitis?American Review of Respiratory Disease, 1991
- Toxic Hepatitis with Isoniazid and RifampinChest, 1991
- Hepatic toxicity in south indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamideTubercle, 1986
- A controlled trial of 6 months' chemotherapy in pulmonary tuberculosis Final report: Results during the 36 months after the end of chemotherapy and beyondRespiratory Medicine, 1984
- Short-Course chemotherapy for tuberculosis with mainly twice-weekly isoniazid and rifampinThe American Journal of Medicine, 1984
- The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamideTubercle, 1977
- Effect of Rifampicin and Isoniazid on Liver FunctionBMJ, 1972
- Sulphadimidine Acetylation Test for Classification of Patients as Slow or Rapid Inactivators of IsoniazidBMJ, 1970
- The use of pyrazinamide plus isoniazid in the treatment of pulmonary tuberculosisTubercle, 1959